Research
Wolfe Research Initiates CytomX Therapeutics With Outperform Rating
CytomX Therapeutics (CTMX) has an average rating of Buy and mean price target of $12.30, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$CTMX
